麻风分枝杆菌DNA旋转酶突变与氟喹诺酮耐药性的系统综述
该研究通过系统综述25项研究、2884株麻风分枝杆菌临床分离株,分析DNA旋转酶基因突变及其与氟喹诺酮耐药性的关联。结果显示3.8%的分离株存在gyrA突变(n=110),0.8%存在gyrB突变(n=6)。研究提出了共识编号系统和三维模型,以助区分耐药相关突变并支持耐药监测。
要点
- 麻风分枝杆菌DNA旋转酶突变见于约4%的临床分离株。
- gyrA突变主要位于91位(68%),gyrB突变较少见。
- 共识编号系统和三维模型有助于评估未知突变对氟喹诺酮耐药性的影响。
核心结论
- DNA旋转酶突变在4%的麻风分枝杆菌临床分离株中观察到。
- 提出的共识编号系统和三维模型有助于解决文献差异并区分氟喹诺酮耐药或敏感相关突变,支持耐药监测。
研究设计与样本
- 系统综述,检索PubMed数据库,纳入报告麻风分枝杆菌临床菌株基因型药敏试验方法和旋转酶基因突变的文献。
- 共纳入25项研究,分析2884株麻风分枝杆菌分离株(其中2236株仅检测gyrA,占77%;755株检测gyrA和gyrB,占26%)。
主要发现
- 3.8%的分离株存在gyrA突变(n=110),其中68%(n=75)位于91位。
- 0.8%的分离株存在gyrB突变(n=6)。
- 文献中与氟喹诺酮耐药相关的替换位置存在不一致。
关键数值与推荐
- gyrA突变频率为3.8%(110/2884),gyrB突变频率为0.8%(6/755)。
- gyrA突变主要位于91位,占68%(75/110)。
临床怎么用
- 建议使用共识编号系统对麻风分枝杆菌gyrA和gyrB突变进行统一编号。
- 可利用三维模型预测未知突变对氟喹诺酮耐药性的潜在影响。
局限性
- 麻风分枝杆菌无法体外培养,抗菌药物耐药性监测主要依赖分子方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The fact that Mycobacterium leprae does not grow in vitro remains a challenge in the survey of its antimicrobial resistance (AMR). Mainly molecular methods are used to diagnose AMR in M. leprae to provide reliable data concerning mutations and their impact. Fluoroquinolones (FQs) are efficient for the treatment of leprosy and the main second-line drugs in case of multidrug resistance. OBJECTIVES: This study aimed at performing a systematic review (a) to characterize all DNA gyrase gene mutations described in clinical isolates of M. leprae, (b) to distinguish between those associated with FQ resistance or susceptibility and (c) to delineate a consensus numbering system for M. leprae GyrA and GyrB. DATA SOURCES: Data source was PubMed. STUDY ELIGIBILITY CRITERIA: Publications reporting genotypic susceptibility-testing methods and gyrase gene mutations in M. leprae clinical strains. RESULTS: In 25 studies meeting our inclusion criteria, 2884 M. leprae isolates were analysed (2236 for gyrA only (77%) and 755 for both gyrA and gyrB (26%)): 3.8% of isolates had gyrA mutations (n = 110), mostly at position 91 (n = 75, 68%) and 0.8% gyrB mutations (n = 6). Since we found discrepancies regarding the location of substitutions associated with FQ resistance, we established a consensus numbering system to properly number the mutations. We also designed a 3D model of the M. leprae DNA gyrase to predict the impact of mutations whose role in FQ-susceptibility has not been demonstrated previously. CONCLUSIONS: Mutations in DNA gyrase are observed in 4% of the M. leprae clinical isolates. To solve discrepancies among publications and to distinguish between mutations associated with FQ resistance or susceptibility, the consensus numbering system we proposed as well as the 3D model of the M. leprae gyrase for the evaluation of the impact of unknown mutations in FQ resistance, will provide help for resistance surveillance.
引用
- Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clin Microbiol Infect. 2021. PMID: 34265461. doi:10.1016/j.cmi.2021.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。